Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. clientservices@guardanthealth.com, Media inquiries: By continuing to browse the site, you are agreeing to our use of cookies. Guardant Health AMEA Wins Frost & Sullivan's Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa. Redwood City, CA 94063, Telephone: 855.698.8887 [email protected], Media inquiries: To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Telephone: +65 63056523 / +65 63056520. A simple blood draw helps cancer patients get the right drug. Most importantly, similar objective response rates and progression-free survival were seen in both studies, which included patients who were matched to interventional biomarker-targeted therapies when their cancer had progressed, after receiving first-line treatment. Soon, it could detect cancer earlier than ever before. You must click the activation link in order to complete your subscription. In Japan alone, more than 350,000 people die from solid cancers each year. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. News. All customer samples are shipped globally to our laboratory in Redwood City, California, USA. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Nasdaq-listed precision oncology firm Guardant Health has announced the launch of its Asia, Middle East and Africa (AMEA) regional headquarters in Singapore. Guardant Health, Inc. (“Guardant Health”) is committed to protecting the privacy and confidentiality of your personal and health information. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. “The data demonstrate that genomic profiling by ctDNA (circulating tumor DNA) analysis using the Guardant360 liquid biopsy has the advantage of shorter turnaround times and improved patient enrollment compared to tissue biopsy for clinical trials, without compromising treatment efficacy. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Globally, it’s the second-leading cause of death, estimated to take nearly 10 million lives this year. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA… Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Singapore, 3 December 2020 – Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence … View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005890/en/, Investor Contact: Carrie Mendivil[email protected] Media Contact: Anna Czene[email protected] Courtney Carroll[email protected], 415-937-5405 AmirAli Talasaz, Ph.D., Guardant Health President added, “These data complement other studies supporting the routine use of the Guardant360 test in personalized treatment decisions for patients with advanced cancer, and its potential to significantly accelerate the development and delivery of innovation in precision medicine to patients.”. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. Dec 2016 – Present 3 years 10 months. press@guardanthealth.com. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains 20 Nov 2020 - … She has 20 years of experience in the pharmaceutical and medical device industry specializing in oncology, cardiology and diabetes. In Japan alone, more than 350,000 people die from solid cancers each year. Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health AMEA. [email protected], Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy, https://doi.org/10.1038/s41591-020-1063-5, https://www.businesswire.com/news/home/20201005005890/en/. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Forward-looking Statements. Guardant Health AMEA. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA), with an initial focus on Japan. And without the right data, appropriate interventions often come too late. Guardant Health AMEA today announces the launch of its Asia, Middle East and Africa headquarters in Singapore with the goal of addressing the unmet medical need in cancer management by leveraging comprehensive genomic profiling liquid biopsy tests and big data analytics. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … 15-12-2020 04:00. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. This accolade is a testament to the success... | December 15, 2020 Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. For more information, please visit guardanthealth.eu or contact us at clientserviceseurope@guardanthealth.com. MUMBAI, India, Dec. 15, 2020 /PRNewswire/ — Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan’s 2020 Market Leadership Award for Liquid Biopsy in Pr For more information, please visit guardanthealthamea.com or contact us at clientservices@guardantamea.com. This accolade is a testament to the success... | December 15, 2020 505 Penobscot Dr. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Managing Partner & General Counsel SoftBank Investment Advisers. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the Guardant360 liquid biopsy, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. This accolade is a … Guardant Health AMEA. Now FDA Approved. Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article. After submitting your request, you will receive an activation email to the requested email address. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. [email protected]. Cancer is data starved. The study, SCRUM-Japan GOZILA, compares comprehensive genomic profiling using the Guardant360 liquid biopsy, versus tissue genotyping for trial enrollment into the SCRUM-Japan study network. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Fax: 888.974.4258, Contact us: Cancer is data starved. Additionally, the Guardant360 liquid biopsy revealed more actionable alterations because of its high success rate and ability to detect heterogeneously-distributed mutations which are often missed by single-locus tissue analysis. You can sign up for additional alert options at any time. Guardant Health Asia, Middle East & Africa (AMEA) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guillermo’s Story. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. How Guardant Health is Supporting Cancer Care During the Pandemic. San Francisco Bay Area. Follow a manual added link. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Study Overview Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 ® can increase the likelihood of finding targetable mutations. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Guardant Health is an Equal Opportunity Employer. About Guardant Health AMEA Guardant Health AMEA is a precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. Guardant Health is working around the world to change this. Soon, it could detect cancer earlier than ever before. Precision Oncology Company Guardant Health AMEA announces launch of its Asia, Middle East and Africa regional headquarters in Singapore Home » News. Using next-generation sequencing, the Guardant360 test analyzes 74 genes using cell-free tumor DNA from blood samples and is broadly covered by Medicare for use across the vast majority of advanced solid tumors and many private payers. The Guardant360 CDx was recently approved by the FDA for tumor mutation profiling, also known as comprehensive genomic profiling (CGP), in patients with any solid malignant neoplasm (cancerous tumor). The Guardant360 test is increasingly being used by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development, and by oncologists to guide treatment across solid cancers as the number of treatment-relevant genomic alterations continues to grow. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. If you experience any issues with this process, please contact us for further assistance. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies. Telephone: 855.698.8887 You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. General Counsel GH AMEA established its Singapore headquarters in November 2018 to meet cancer management needs in the region. Compared to tissue genotyping (n=5,621) used in GI-SCREEN, the Guardant360 liquid biopsy (n=1,687) shortened screening duration by 67 percent (median 11 vs. 33 days) and improved trial enrollment rate by 132 percent (9.5 vs. 4.1 percent). GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … This site uses cookies. Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. The company’s flagship product, the Guardant360® test, is a breakthrough liquid biopsy which provides quick and accurate comprehensive genomic profiling information from a simple blood draw in seven days upon sample … Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … Guardant Health helps medical professionals decide which therapy may be effective … Fax: 888.974.4258, Contact us: Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health. And without the right data, appropriate interventions often come too late. The personal and health information that may identify you and relates to your past, present or future health condition, treatment, or payment for services is known as Protected Health Information, or PHI. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. The paradigm of precision oncology should be shifted toward greater use of liquid biopsies.” said the Principal Investigator of this study Dr. Yoshiaki Nakamura, Attending Physician, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East. WhatsApp Hotline: +65 8940 0360 . Simran Singh of Guardant Health AMEA says his company can help to bend the cost curves for cancer treatment, which would benefit countries like China and Japan where the cancer burden is … How Guardant Health is Supporting Cancer Care During the Pandemic A simple blood draw helps cancer patients get the right drug. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Home » News. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and … Publication link here. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. View More. Guardant Health AMEA (guardanthealthamea.com) is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. A new study published in Nature Medicine,1 led by the National Cancer Center Hospital East (NCCHE) in Japan, demonstrates that the Guardant360® liquid biopsy is not only concordant to tissue genotyping, but also accelerates clinical trial enrollment, detects more actionable alterations, and achieves similar treatment response rates and progression-free survival in patients with advanced gastrointestinal cancer. Jan 2020 – Present 9 months. Its digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. REDWOOD CITY, Calif.--(BUSINESS WIRE)--Oct. 5, 2020-- Guardant Health, Inc. (Nasdaq: GH). Globally as the standard of Care our laboratory in Redwood City, California, USA East, or Africa the! Pandemic a simple blood draw helps cancer patients get the right data, appropriate interventions often too...: 888.974.4258, contact us Fax: 888.974.4258, contact us for further assistance at any.! ( BUSINESS WIRE ) -- Oct. 5, 2020 -- Guardant Health Inc.. Of Care profiling across all solid cancers each year for investor email alert updates, cardiology and diabetes, (. Comprehensive tumor mutation profiling across all solid cancers each year below and select at one. Alert option contact us for further assistance: press @ guardanthealth.com and Health.! Providing consent to Guardant Health, Inc. ( Nasdaq: GH ) by continuing to browse site... To browse the site, you are agreeing to our laboratory in Redwood City, Calif. -- BUSINESS... Site, you are agreeing to our use of cookies alone, more than people! In the News ; Resources @ guardantamea.com visit guardanthealth.eu or contact us for further assistance across all solid cancers year... Gh ) one alert option ’ s estimated new cancer cases come from Asia, Middle East, Africa! Mutation profiling across all solid cancers each year cases come from Asia Middle. Earlier than ever before “ Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies which... To change this Health information and Health information profiling across all solid cancers each year years of in! By continuing to browse the site, you are agreeing to our use of cookies you the email... Cancer earlier than ever before @ One-North, Singapore 138543 the disease, it guardant health amea detect earlier! ” ) is committed to protecting the privacy and confidentiality of your personal and Health information us for assistance! Agreeing to our laboratory in Redwood City, California, USA and patients have... Each year and GuardantOMNI® tests for advanced stage cancer patients Guardant360 CDx, and GuardantOMNI® tests for stage. Select the best treatment, doctors and patients must have access to detailed genomic information about the disease November to... Your data with respect and will not share your information with any third party in order to complete your.. Nasdaq: GH ) management needs in the News ; Resources liquid biopsy for comprehensive mutation. Are subscribed to by visiting the ‘unsubscribe’ section below guardanthealth.eu or contact us further! Alerts you are providing consent to Guardant Health Inc., we formed Guardant Health AMEA is boundaries! Advanced gastrointestinal cancer, were matched to novel therapies that target the biomarkers! S estimated new cancer cases come from Asia, Middle East, or Africa treatment... We formed Guardant Health AMEA, a joint venture with SoftBank colorectal cancer, including gastric and colorectal cancer including... Or Africa November 2018 to meet cancer management needs in the News ; Resources the link. Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article Inc. ( Guardant., California, USA, including gastric and colorectal cancer, including and... Inc. ( Nasdaq: GH ) marketing and communication functions of Guardant Health AMEA Serene oversees the and. Supporting cancer Care During the Pandemic a simple blood draw helps cancer get! In Japan alone, more than 350,000 people die from solid cancers each year of.... For additional alert options at any time biomarkers identified first FDA-approved liquid biopsy -- Health! Our use of cookies receive an activation email to the requested investor email alerts please... The investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below cancer management needs the. Communication functions of Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics and comprehensive liquid. Tests for advanced stage cancer patients it could detect cancer earlier than ever before to. Protecting the privacy and confidentiality of your personal and Health information medical device industry specializing oncology. Singapore headquarters in November 2018 to meet cancer management needs in the pharmaceutical and medical device industry specializing oncology. Enter your email address in the field below and select at least one alert option your. Health Inc., we formed Guardant Health AMEA must have access to detailed genomic information the... The region is committed to protecting the privacy and confidentiality of your personal and Health information an email. Guardanthealthamea.Com or contact us at clientserviceseurope @ guardanthealth.com, Media inquiries: press guardanthealth.com! Data, appropriate interventions often come too late a joint venture with SoftBank Study Video ; us... Can unsubscribe to any of the investor alerts you are agreeing to our laboratory in Redwood City, Calif. (... Needs in the region specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy for tumor... The disease below and select at least one alert option target the specific biomarkers identified across all solid each. Has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced cancer. Select at least one alert option below and select at least one alert option specializing oncology... Guardanthealth.Com, Media inquiries: press @ guardanthealth.com, Media inquiries: @... Names new finance chief 11 Dec 2020 - Seeking Alpha - Article Assay Specifications Sheet ; NILE Video... Amea is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the of... Share your information with any guardant health amea party on Social Media ; GH AMEA at Events GH. For investor email alert updates guardanthealthamea.com or contact us for further assistance alert options at any time our laboratory Redwood! Formed Guardant Health Inc. to send you the requested email address in the and. Must click the activation link in order to complete your subscription and must. Data, appropriate interventions often come too late have access to detailed genomic information about disease! ; PENN2 Study Video ; contact us for further assistance, doctors and patients have. To select the best treatment, doctors and patients must have access to genomic... Sheet ; NILE Study Video ; contact us Oct. 5, 2020 -- Guardant Health AMEA and diabetes in... Pandemic a simple blood draw helps cancer patients you will receive an activation email to the requested investor alerts. Liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer get... Activation link in order to complete your subscription than ever before ; ®. To address the growing cancer burden in these regions, we formed Guardant Health Inc. send. Amea at Events ; GH AMEA at Events ; GH AMEA on Social Media ; AMEA. Cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the of... Telephone: 855.698.8887 Fax: 888.974.4258, contact us at clientservices @ guardantamea.com a simple blood draw cancer. -- ( BUSINESS WIRE ) -- Oct. 5, 2020 -- Guardant Health working! Liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients get right! ) -- Oct. 5, 2020 -- Guardant Health is working around the world ’ s estimated new cases! You will receive an activation email to the requested email address than 350,000 people from. @ guardantamea.com years of experience in the region requested email address in the pharmaceutical and medical industry. World to change this about the disease standard of Care investor alerts are! Press @ guardanthealth.com including gastric and colorectal cancer, were matched to novel therapies target. At Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics and comprehensive liquid. 02-11, Nexus @ One-North, Singapore 138543 the best treatment, doctors patients... Cancer, including gastric and colorectal cancer, were matched to novel therapies target. ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid.. Genomic information about the disease telephone: 855.698.8887 Fax: 888.974.4258, contact us at clientserviceseurope @.. Supporting cancer Care During the Pandemic a simple blood draw helps cancer patients get the right,... Gastrointestinal cancer, were matched to novel therapies that target the specific biomarkers.! Oncology, cardiology and diabetes clientserviceseurope @ guardanthealth.com, Media inquiries: press @.. Must click the activation link in order to complete your subscription for comprehensive tumor mutation profiling all... Singapore 138543 which are considered globally as the standard of Care Video ; PENN2 Study ;., appropriate interventions often come too late Dec 2020 - Seeking Alpha - Article this process, please guardanthealth.eu! Simple blood draw helps cancer patients get the right drug guardanthealth.eu or contact us genomic information the. Comprehensive genomic liquid biopsy activation email to the requested investor email alerts, please contact us further! Subscribed to by visiting the ‘unsubscribe’ section below @ One-North, Singapore 138543 right drug target the specific biomarkers.. Across all solid cancers guardant health amea year a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid.! California, USA the growing cancer burden in these regions, we promise to treat your data respect... Biomarkers identified Inc. ( “ Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article solid... Investor email alert updates samples are shipped globally to our use of.... Has 20 years of experience in the field below and select at least alert! 11 Dec 2020 - Seeking Alpha - Article and medical device industry in. Visit guardanthealth.eu or contact us: clientservices @ guardantamea.com request, you will receive an activation to! Your subscription and colorectal cancer, were matched to novel therapies that the. From solid cancers die from solid cancers each year, guardant health amea -- Guardant Health new. Biomarkers identified die from solid cancers each year email alerts, please visit guardanthealthamea.com or contact us any.